Back to top
more

Infinity Pharmaceuticals, Inc. (INFI)

(Delayed Data from NSDQ)

$1.71 USD

1.71
99,328

+0.06 (3.64%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.72 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Infinity Pharma (INFI) Stock Up on Advancing Cancer Study

by Zacks Equity Research

Infinity Pharma (INFI) provides insights on the phase II MARIO-8 study design. The study will evaluate eganelisib for squamous cell cancer of the head and neck.

Earnings Preview: Catalent (CTLT) Q3 Earnings Expected to Decline

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Infinity (INFI) delivered earnings and revenue surprises of 8.33% and 95.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Infinity Pharmaceuticals (INFI) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 6.73% and 23.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Acutus Medical, Inc. (AFIB) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 158.57% and 3.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -55.56% and 15.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Down 44.4% in 4 Weeks, Here's Why Infinity (INFI) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Infinity (INFI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Infinity (INFI) delivered earnings and revenue surprises of -140% and 91.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Altimmune, Inc. (ALT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.04% and 99.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 55.41% and 7.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 28.57% and 78.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

KalVista (KALV) Stock Continues to Decline: Here's Why

by Zacks Equity Research

The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.

Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug

by Zacks Equity Research

The FDA Oncologic Drugs Advisory Committee votes against Spectrum's (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations. Stock down.

Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal

by Zacks Equity Research

Pacira's (PCRX) phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for bunionectomy meets primary and secondary endpoints.

Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Infinity (INFI) delivered earnings and revenue surprises of 7.14% and 1.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Infinity (INFI) delivered earnings and revenue surprises of 0% and 65.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?

by Zacks Equity Research

Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.

Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Infinity (INFI) delivered earnings and revenue surprises of 7.14% and 10.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.94% and 42.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 40% and 204.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 76.25% and 30.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

JAZZ's Xywav Gets Orphan Drug Exclusivity for Hypersomnia

by Zacks Equity Research

The FDA bestows an Orphan Drug Exclusivity to Jazz's (JAZZ) Xywav for treating idiopathic hypersomnia in adults. This is the second Orphan Drug Exclusivity for the drug.

Are Options Traders Betting on a Big Move in Infinity (INFI) Stock?

by Zacks Equity Research

Investors need to pay close attention to Infinity (INFI) stock based on the movements in the options market lately.

Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Infinity (INFI) delivered earnings and revenue surprises of 14.29% and -5.31%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?